Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		5 Months Ended	6 Months Ended
	Jan. 29, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2022
Operating expenses:
Research and development	$ 662	$ 53,651	$ 18,134	$ 28,276	$ 90,504
General and administrative	121	14,763	11,841	17,436	29,148
Change in fair value of contingent value rights	0	0	11,312	11,312	1,980
Acquired in-process research and development	0	0	0	220,454	0
Loss from operations	(783)	(68,414)	(41,287)	(277,478)	(121,632)
Interest (expense) income, net	(9)	(1,628)	27	35	(3,024)
Amortization of debt discount	(37)	0	0	0	0
Other income (expense), net	0	5,359	(191)	(2,699)	5,555
Loss before income taxes	(829)	(64,683)	(41,451)	(280,142)	(119,101)
Income taxes	0	(22)	0	0	58
Net loss	(829)	(64,661)	(41,451)	(280,142)	(119,159)
Other comprehensive loss:
Foreign currency translation adjustment	107	(1,124)	1,094	3,315	(1,830)
Total comprehensive loss	$ (722)	$ (65,785)	$ (40,357)	$ (276,827)	$ (120,989)
Net loss per ordinary share - basic (in dollars per share)		$ (0.69)	$ (0.65)	$ (4.89)	$ (1.29)
Net loss per ordinary share - diluted (in dollars per share)		$ (0.69)	$ (0.65)	$ (4.89)	$ (1.29)
Weighted average ordinary shares outstanding - basic (in shares)		94,109,089	63,516,656	57,309,693	92,317,172
Weighted average ordinary shares outstanding - diluted (in shares)		94,109,089	63,516,656	57,309,693	92,317,172